ライフサイエンスコーパス: topical

1 re the frequency of complete resolution with topical 5-FU treatment and the rate of OSSN recurrence.

2 time-intensity taste analysis revealed that topical addition of both l- and d-MSpG enhanced the perc

3 inal neuroprotective effects of systemic and topical administration (eye drops) of GLP-1R agonists in

4 has also been used as an analgesic, and its topical administration is approved for the treatment of

5 Single topical administration of 25 pmol of 12 increased tear v

6 ion using an inducible promoter activated by topical administration of doxycycline achieved the same

7 In this study, the effects of topical administration of HOCl hydrogel (0.05%) on atopi

8 This study evaluates effects of topical administration of probiotic bacteria of the genu

9 ired MSC recruitment that is reversed by the topical administration of recombinant GPNMB protein to t

10 ntly suppressed skin inflammation induced by topical administration of the TLR7 agonist imiquimod.

11 Topical administration provides an attractive route for

12 In groups C and EP, topical administrations were performed using a sham susp

13 lving genetically modified mice treated with topical agents and human dermatological conditions, such

14 compounds have the potential to be effective topical agents for treating respiratory inflammatory dis

15 an unmet dermatological need for innovative topical agents that achieve better longterm outcomes wit

16 sm used in rinse-off formulations to deliver topical agents to the skin and hair; this process produc

17 ssions or emergency procedures have become a topical and controversial issue for the UK National Heal

18 Both topical and intradermal gentamicin administration induce

19 pilot trial assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients wi

20 Topical and intradermal gentamicin suppresses nonsense m

21 hich improved with corticosteroid treatment (topical and intralesional) alone or in combination with

22 Bottom Line: Use of topical and systemic antibiotics for acne is associated

23 the reported therapeutic modalities, such as topical and systemic corticosteroids, systemic immunomod

24 corticosteroids, systemic immunomodulators, topical and systemic retinoids, and laser, HHD can still

25 The pipeline of more targeted topical and systemic therapies is expanding based on our

26 Treatment included a combination of topical and systemic therapies, such as corticosteroids,

27 ICRS were inserted under topical anesthesia after creating a corneal tunnel with

28 limited mobility, sutureless incisions, and topical anesthesia also have become key components of st

29 ry of PTSD were more likely to have received topical anesthesia with or without sedation.

30 sisted 9.5-mm diameter lamellar pocket under topical anesthesia.

31 This validates the topical anti-inflammatory properties of this plant and p

32 r, our results show that IVM is endowed with topical anti-inflammatory properties that could have imp

33 calculating the proportion filling 1 or more topical antibiotic prescription within 14 days of initia

34 te conjunctivitis, 198 462 (58%) filled >/=1 topical antibiotic prescriptions; 38 774 filled prescrip

35 Topical antibiotic was not shown to add to the effective

36 acute conjunctivitis fill prescriptions for topical antibiotics and factors associated with antibiot

37 effect of topical povidone-iodine 1.25% and topical antibiotics commonly available in the developing

38 vidone-iodine 1.25% ophthalmic solution with topical antibiotics for treatment of bacterial keratitis

39 t povidone-iodine and rates with and without topical antibiotics from Diabetic Retinopathy Clinical R

40 in areas of the world where use of effective topical antibiotics may not be an option.

41 Topical antibiotics remain the best treatment for bacter

42 recent review found all commonly prescribed topical antibiotics to be equally effective.

43 e vs oral placebo; all participants received topical antifungal eyedrops.

44 Alternaria alternata, which we treated with topical antifungal medication.

45 Topical antimicrobial agents should not be applied to th

46 We used a trial design formulating C-82 for topical application and conducting a placebo-controlled,

47 These data show that topical application of 0.5% PVI could promote acute skin

48 We found that topical application of 15d-PGJ2 cream for 15min directly

49 Furthermore, topical application of a JP-153-loaded microemulsion aff

50 e we show that in both mouse and human skin, topical application of a mitochondrially targeted antiox

51 al keratinocytes (RXR-alphabeta(ep-/-)) or a topical application of active vitamin D3 (VD3) and/or al

52 Topical application of Aldara cream, containing the Toll

53 ital antigen-specific immune responses after topical application of an adjuvanted antigen formulation

54 Today, formulations for the topical application of ATRA rely on creams and emulsions

55 In vivo experiments show that the topical application of c-Myc siRNAs delivered by SPACE-E

56 Topical application of compound 48/80, an MC secretagogu

57 Congruently, chronic topical application of D3 inhibits ionizing radiation-in

58 more susceptible to contact dermatitis after topical application of dinitrofluorobenzene, and show en

59 Topical application of docosahexaenoic acid (DHA), a rep

60 Notably, topical application of epidermal lipids from wild-type o

61 We have previously reported that the topical application of erythropoietin (EPO) to cutaneous

62 Topical application of honokiol (0.5 and 1.0 mg/cm(2) sk

63 Topical application of Hsp90alpha-Delta mutant protein p

64 vation of Toll-like receptor 7/8 by means of topical application of imiquimod is the most commonly us

65 n with Kr-h1 and E93 was also studied by the topical application of JH analog, methoprene, to N5.

66 Topical application of OG but not 5-(tetradecyloxy)-2-fu

67 Topical application of pathogen-specific double-stranded

68 Here, we show that topical application of polymeric microbeads functionaliz

69 o, micro-coating channels (MCCs) followed by topical application of powder drug-coated array patches

70 Topical application of thapsigargin, which inhibits the

71 significantly upregulated IL-17f, and IL-22; topical application of the IL-23 aptamer decreased both

72 s to neural activity (functional hyperemia), topical application of vasodilators, and decreases in bl

73 In conclusion, topical application offers a direct and efficient delive

74 Topical application on the dural surface of the auditory

75 The anti-inflammatory activity of 5-8 after topical application was investigated in two mouse models

76 Three days after topical application, the MSCs homed to the injured paren

77 t result in low ocular bioavailability after topical application.

78 ant cells and silencing of homologous RNA on topical application.

79 , and commensal organisms also in trials for topical application.

80 Acute topical applications of ARN077 attenuated key signs of D

81 and show enhanced inflammatory lesions after topical applications of phorbol ester.

82 The topical arm tested 0.1% gentamicin ointment or placebo a

83 the published literature on the efficacy of topical atropine for the prevention of myopic progressio

84 rally in the study eye; the fellow eye began topical bimatoprost 0.03% once daily.

85 All dose strengths were comparable to topical bimatoprost in overall IOP reduction through wee

86 A topical bimatoprost ocular insert was compared with twic

87 the injection procedure was more common with topical bimatoprost than Bimatoprost SR (17.3% vs 6.7% o

88 hs of implant, respectively, vs 8.4 mm Hg in topical bimatoprost-treated pooled fellow eyes (data cen

89 We, therefore, urge against the use of topical brimonidine as a hemostatic agent until its safe

90 Topical brimonidine, 0.33%, gel can result in systemic c

91 Topical brimonidine, 0.33%, gel has been reported for th

92 ermine the risk of systemic toxic effects of topical brimonidine, 0.33%, gel when used for hemostasis

93 98671 homozygotes were less likely to report topical calcineurin inhibitor use (OR, 0.16; 95% CI, 0.0

94 tant topical corticosteroids with or without topical calcineurin inhibitors where inadvisable for top

95 ches (with either topical corticosteroids or topical calcineurin inhibitors) in mild AD cases or the

96 d's AD required the use of topical steroids, topical calcineurin inhibitors, or other medications wit

97 and among all patients that had discontinued topical calcineurin inhibitors, those with the rs1898671

98 Topical carmustine and intravenous O6-benzylguanine.

99 e 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage

100 mphoma, MF type, to evaluate treatment using topical carmustine plus 2 subsequent daily doses of intr

101 e, but not in Tlr4-d or MyD88(-/-) mice with topical challenge.

102 ery, radiotherapy, systemic chemotherapy, or topical chemotherapy) vs treatment-naive BCCs.

103 g without genetic engineering, and fuels the topical controversy of reviving long extinct species.

104 Topical corticosteroid (TCS) phobia refers to the negati

105 oral corticosteroids to less than 10 mg/d or topical corticosteroid drops to less than 2 drops daily,

106 art of AAT and subsequently at the time that topical corticosteroid therapy was initiated.

107 Intensified topical corticosteroid therapy was started immediately a

108 grade II dermatitis that was unresponsive to topical corticosteroid therapy.

109 INTERPRETATION: Dupilumab added to standard topical corticosteroid treatment for 1 year improved ato

110 After 8 days of topical corticosteroid treatment visual acuity was worse

111 i-Programmed cells Death-1 was stopped and a topical corticosteroid treatment was administrated.

112 for a total of 6 doses in addition to daily topical corticosteroid treatment.

113 ds in the last 3 months (aHR, 2.23); current topical corticosteroid use [>/=8x/day vs. none] (aHR, 2.

114 , sex, prior oral corticosteroid dose, prior topical corticosteroid use, and concomitant immunosuppre

115 Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted

116 6, more patients who received dupilumab plus topical corticosteroids achieved the coprimary endpoints

117 udy (HEDS) I showed a significant benefit of topical corticosteroids and oral acyclovir for stromal k

118 g atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, sy

119 Topical corticosteroids could be tapered, stopped, or re

120 the risk benefit associated with the use of topical corticosteroids for the management of inflammato

121 topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-sever

122 s by using proactive approaches (with either topical corticosteroids or topical calcineurin inhibitor

123 % [125 patients] who received dupilumab plus topical corticosteroids qw and 39% [41 patients] who rec

124 ds, especially when the cumulative dosage of topical corticosteroids throughout the pregnancy is very

125 hoose whether to stop or continue once-daily topical corticosteroids to maximize compliance.

126 and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical cort

127 41 patients] who received dupilumab q2w plus topical corticosteroids vs 12% [39 patients] who receive

128 atopic dermatitis and inadequate response to topical corticosteroids were enrolled at 161 hospitals,

129 Treatments with systemic and topical corticosteroids were not significant risk factor

130 nts with recurrent nasal polyposis receiving topical corticosteroids who required surgery, mepolizuma

131 All three groups were given concomitant topical corticosteroids with or without topical calcineu

132 were randomly assigned to dupilumab qw plus topical corticosteroids, 106 to dupilumab q2w plus topic

133 83%) patients who received dupilumab qw plus topical corticosteroids, 97 (88%) patients who received

134 (31.7%), respectively, made comparisons with topical corticosteroids, and 25 (64.1%) and 15 (36.6%),

135 l corticosteroids, 106 to dupilumab q2w plus topical corticosteroids, and 315 to placebo plus topical

136 wever, maternal use of potent to very potent topical corticosteroids, especially when the cumulative

137 ion, even using higher doses of systemic and topical corticosteroids, is of importance in preventing

138 Current clinical treatments use topical corticosteroids, which broadly and transiently s

139 mmon in patients treated with dupilumab plus topical corticosteroids-treated patients than in patient

140 At baseline, 56 eyes (75%) were on topical corticosteroids.

141 cal corticosteroids, and 315 to placebo plus topical corticosteroids.

142 calcineurin inhibitors where inadvisable for topical corticosteroids.

143 in this series had an inadequate response to topical corticosteroids.

144 s than in patients treated with placebo plus topical corticosteroids.

145 e response associated with keratitis include topical corticosteroids.

146 12% [39 patients] who received placebo plus topical corticosteroids; p<0.0001) and EASI-75 (64% [204

147 This review will provide topical coverage of target validation and drug discovery

148 Herein we present a new concept in topical delivery of retinoids by covalently bonding the

149 ation of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2

150 This comprehensive review summarizes the topical developments in the field of luminescent MOF and

151 stratum corneum and therefore enhancement of topical drug delivery, for two decades the technique has

152 offer, as a result, potential sites in which topical drug formulations might be sequestered post-pora

153 nt to lower intraocular pressure is based on topical drugs, laser therapy, and surgical intervention

154 We found that topical EPO treatment of the burns accelerated their hea

155 , a crucial constituent of the ECM, into the topical EPO-containing gel, can potentiate the accelerat

156 were compared before and five minutes after topical exposure to vasoconstrictors (50 mM KCl and 20 n

157 The costs of applying topical fluoride were also estimated assuming the work w

158 hs from 281 participants randomized to apply topical fluorouracil or placebo were evaluated at baseli

159 To investigate the effect of topical fluorouracil, 5%, cream on photoaging using vali

160 Participants were randomized to apply topical fluorouracil, 5%, cream or a vehicle control cre

161 ment in photoaging with a standard course of topical fluorouracil, 5%, cream, a finding that may be a

162 mopreventive effects of a standard course of topical fluorouracil.

163 pproach to study the differential effects of topical formulations using a limited sample size.

164 Topical gentamicin corrected dermal-epidermal separation

165 esults indicate the therapeutic potential of topical gentamicin for NPPK.

166 erally controlled compassionate use study of topical gentamicin in which five NPPK patients with c.79

167 how in vitro and in vivo that treatment with topical glucocorticoids leads to rapid restoration of gl

168 Topical glucocorticosteroids are considered an efficient

169 Safe and acceptable topical HIV prevention methods that target the rectum ar

170 It has been reported that topical hypochlorous acid (HOCl) formulations lead to re

171 ndoscopic imaging of human bladder cancer by topical (i.e. intravesical) administration of QD-conjuga

172 Topical IDR-1002 treatment successfully dampened PMA-ind

173 d closure in vivo, which could be rescued by topical IL-27 treatment.

174 reported modest clinical 3-year benefit for topical imiquimod compared with surgery for superficial

175 the IL-23-induced ear swelling model and the topical imiquimod model, and significantly reduced the n

176 ed benefit for lesions that respond early to topical imiquimod.

177 Topical immunization of conditional knockout mice with E

178 lence was seen for the DeltaBbpacC strain in topical insect bioassays using larvae from the greater w

179 New topical insecticide formulations have proven to be effec

180 polymer and polypeptide layers, which is of topical interest for interface studies, such as membrane

181 ing the proof of concept of the potential of topical intestinal TGR5 agonists as therapeutic agents i

182 a comprehensive review regarding the various topical, intracavitary, and intravenous hemostatic techn

183 Topical intraocular pressure lowering therapy had to be

184 Rescue topical IOP-lowering medication or a single repeat treat

185 Within this framework, here we address topical issues at the intersection of DLBCL biology and

186 Our results show that topical IVM improved allergic skin inflammation by reduc

187 improvement in VO2 peak , adaptation to the topical LCHF diet negated performance benefits in elite

188 y Local Eye symptoms than those treated with topical medications (eg, at 12 months, 153 of 269 [56.9%

189 We conclude that topical mevastatin accelerates wound closure by promotin

190 Of note, topical mevastatin stimulated epithelialization and angi

191 ns can be applied to increase the potency of topical microbicides and vaccine-elicited antibodies.

192 e was low- to moderate-quality evidence that topical minoxidil (2% and 5%) was associated with improv

193 otic monotherapy, combination treatment with topical modalities, and limiting the duration of oral an

194 94 signaling pathways were activated in the topical MSCs transplanted onto the cortex of brain injur

195 Topical MSCs triggered earlier astrocytosis and reactive

196 Topical nasal corticosteroids are the treatment of choic

197 Treatment Trial (MUTT) I showed a benefit of topical natamycin over topical voriconazole for fungal u

198 with no new treatments since the 1960s when topical natamycin was introduced.

199 Treatment Trial (MUTT) II became available, topical natamycin, 5%, was added for all patients.

200 After 39 participants (16.3%) were enrolled, topical natamycin, 5%, was also added.

201 it from the addition of oral voriconazole to topical natamycin, and physicians should consider prescr

202 Patients were randomized (1:1) to topical nepafenac 0.3% or vehicle once-daily starting th

203 Topical nepafenac 0.3% reduces PCME in patients with pre

204 Topical nepafenac 0.3% significantly reduces the inciden

205 ted vasopressors: intraosseous phentolamine, topical nitroglycerin ointment, and intraarterial verapa

206 Define the effectiveness of a topical non-steroidal anti-inflammatory drug (NSAID) add

207 Here we sought to determine whether topical nonsense-suppression (readthrough) therapy using

208 To describe the effect of routine use of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on

209 ents who had a perioperative prescription of topical NSAIDs filled in addition to topical steroids we

210 Topical NSAIDs were associated with a modest reduction o

211 Herein, we determined whether topical or intradermal gentamicin administration induces

212 ears of effort and investment, there are few topical or systemic medications for skin wounds.

213 yte-derived GC synthesis protected skin from topical phorbol 12-myristate 13-acetate-induced inflamma

214 Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became ava

215 t is recommended for adequate penetration of topical photosensitizing agents and subsequent protoporp

216 significant difference between the effect of topical povidone-iodine 1.25% and topical antibiotics co

217 this, we sought to determine the effects of topical reformulations of the angiotensin type 1 recepto

218 In this Topical Review we discuss the experimental data which su

219 In this topical review we focus on the role of the Notch signall

220 References for this topical review were identified by searches of PubMed and

221 loaded with cytotoxic drugs applied via the topical route, can be a promising strategy for improving

222 Topical solenopsin derivatives normalized cutaneous hype

223 nvironmentally sustainable and easy to adopt topical spray.

224 oral suspension (BOS), a novel muco-adherent topical steroid formulation, to reduce symptoms and esop

225 substitution of the most affordable generic topical steroid from the corresponding potency class may

226 uld result from substitution of the cheapest topical steroid from the corresponding potency class.

227 Anecdotal use of topical steroid oral prophylaxis has been reported in pa

228 With topical steroid therapy 5 times per day during the first

229 e may be treated effectively with aggressive topical steroid therapy and lubrication.

230 With hourly topical steroid therapy none of the patients developed C

231 wer adverse-effect profile than conventional topical steroid treatments or other medical or surgical

232 idal anti-inflammatory drug (NSAID) added to topical steroid use after uncomplicated phacoemulsificat

233 nt savings from substitution of the cheapest topical steroid within the corresponding potency class w

234 ntraocular inflammation that resolved with a topical steroid.

235 rneal findings, resolution was achieved with topical steroids and lubrication, whereas some patients

236 Although topical steroids are among the most commonly prescribed

237 Medicare Part D expenditures on topical steroids between 2011 and 2015 were $2.3 billion

238 To compare standard and frequent topical steroids for postsurgical macular edema (ME).

239 erved in 6 eyes (7.5%) and was reversed with topical steroids in all cases.

240 Topical steroids might reduce stomatitis incidence and s

241 pical steroids were compared to those taking topical steroids only.

242 Patients' out-of-pocket spending for topical steroids over the same period was $333.7 million

243 Most topical steroids prescribed were generic drugs.

244 se in Medicare and out-of-pocket spending on topical steroids that is driven by higher costs for gene

245 tion of topical NSAIDs filled in addition to topical steroids were compared to those taking topical s

246 shed new light on the mechanism of action of topical steroids, and demonstrates the critical role of

247 Medicare and patient out-of-pocket costs for topical steroids, and to model potential savings that co

248 of whether a child's AD required the use of topical steroids, topical calcineurin inhibitors, or oth

249 D participants who filled prescriptions for topical steroids.

250 therapies and were generally manageable with topical steroids.

251 recedes PPK onset, which can be prevented by topical sulforaphane-mediated activation of NRF2.

252 immune disease and/or malignancy, as well as topical, systemic, and surgical treatments received.

253 ntraocular pressure (IOP) >22 mm Hg, despite topical/systemic medications.

254 und implications for lymphedema treatment as topical tacrolimus is FDA-approved for other chronic ski

255 Topical therapeutic intervention with SAHM1 or a control

256 ese finding can be used to inform the design topical therapeutics to mitigate allergic responses in s

257 that flavones may have clinical potential as topical therapeutics, particularly in T2R38 AVI/AVI indi

258 To facilitate development of topical therapeutics, we need an efficient model for ass

259 of intrapatient target lesions treated with topical therapeutics.

260 ave important clinical implications, because topical therapies that target IFN-gamma signaling in ker

261 mprovement in PASI score of 33%, with use of topical therapy (60%), biological therapy (66%, mostly a

262 Among these products, AgNP topical therapy is proposed for treating patients with u

263 Topical therapy was used in 82.7%, and 34.2% received lo

264 re plaque psoriasis who had not responded to topical therapy were randomly assigned with an interacti

265 Here using mouse models, we show that topical therapy with tacrolimus, an anti-T-cell immunosu

266 ipants received any antibiotics (systemic or topical therapy) within 1 month before the study.

267 he human nail remains a difficult challenge; topical therapy, in particular, is limited by very poor

268 nts were excluded who were receiving chronic topical therapy, such as glaucoma medications, or had a

269 nvolvement leads to the inappropriate use of topical therapy, the standard of care for causes of cica

270 cular surface pyogenic granulomas respond to topical timolol treatment, which has a lower adverse-eff

271 ldren's Hospital from 2014 to 2016 with only topical timolol, 0.5%, twice daily for a minimum of 21 d

272 wild-type mice a Western diet or by applying topical TLR7/8 (Toll-like receptor) agonists.

273 in murine chest wall mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod.

274 Topical treatment of AhR-sufficient mice with tapinarof

275 we propose that repurposing statin drugs for topical treatment of DFUs may offer another option for m

276 Topical treatment of mice with TIP39 accelerated wound r

277 in mice and is therefore an interesting new topical treatment opportunity in asthmatic patients.

278 increased in K14CreERT;DLX3(fl/fl) skin, and topical treatment with an inhibitor of STAT3 activation

279 apinarof (GSK2894512) is a naturally derived topical treatment with demonstrated efficacy for patient

280 Importantly, topical treatment with fibronectin restored the epiderma

281 mice upon induction of skin inflammation by topical treatment with imiquimod cream (Aldara).

282 Topical treatment with NaNO2 (10 muM) enhanced corneal e

283 These results suggest that topical treatment with PEDF+DHA promotes corneal nerve r

284 172 individuals with bacterial keratitis to topical treatment with povidone-iodine or antibiotics (n

285 Topical treatment with SR1001 reduces epidermal and derm

286 Topical treatment with vemurafenib in two wound-healing

287 rolled IOP (34.5 +/- 11 mmHg), under maximum topical treatment, in a period of 2 to 6 months followin

288 Recommended first-line topical treatments include neuroregenerative and anti-in

289 lammatory disease, to assess the efficacy of topical treatments.

290 after 16 weeks of successful treatment with topical triamcinolone.

291 investigated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil

292 rgets for cutaneous inflammation and suggest topical usage of inhibitory ligands as an approach to tr

293 Topical use of B. lactis HN019 promotes a protective eff

294 ed by hepatic microsomes, which supports its topical use.

295 We explored topical vaginal application as an approach to initiate l

296 Topical vaginal estrogen treatment increased (p < 0.001)

297 I showed a benefit of topical natamycin over topical voriconazole for fungal ulcers, particularly amo

298 zole or a placebo (all participants received topical voriconazole, 1%).

299 All patients received topical voriconazole, 1%, and after the results of the M

300 In vivo, topical WR12 and D-IK8 significantly reduced both the ba